Biocytogen Pharmaceuticals (Beijing) (HKG:2315) expects to record a net profit between 20 million yuan and 40 million yuan for 2024, against a loss of 383 million yuan logged for 2023, a Monday Hong Kong bourse filing said.
The pharmaceutical company attributed the expected turnaround to a rapid increase in sales revenue and high gross profit margins from increased sales of antibody molecules to overseas customers, domestic and overseas growth in gene editing animal model business, cost control, and reduced research and development expenses during the reporting year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.